

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	Little Green Pharma Ltd
<b>ACN</b>	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Angus McDougall Caithness
<b>Date of last notice</b>	4 October 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Banquo Consulting Pty Ltd - Mr Caithness is a director  Angus Caithness SMSF Pty Ltd as trustee for the Caithness Superannuation Fund - Mr Caithness is a director of the trustee and beneficiary
<b>Date of change</b>	15 April 2024

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>No. of securities held prior to change</b></p>	<p><u>Direct</u>  5,751,441 Ordinary shares  100,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024  1,000,000 Retention Share Rights</p> <p><u>Indirect</u>  <i>Banquo Consulting Pty Ltd</i>  5,548,000 Ordinary shares  500,000 Class F Performance Rights  500,000 Class G Performance Rights  500,000 Class H Performance Rights  500,000 Class I Performance Rights  500,000 Class J Performance Rights  500,000 Class K Performance Rights  32,000 Share Rights</p> <p><i>Angus Caithness SMSF Pty Ltd as trustee for the Caithness Superannuation Fund</i>  150,000 Ordinary shares  150,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024</p>
<p><b>Class</b></p>	<p>(a) Fully paid ordinary shares  (b) Share rights</p>
<p><b>Number acquired</b></p>	<p>(a) 36,000 Fully paid ordinary shares</p>
<p><b>Number disposed</b></p>	<p>(b) 36,000 Share Rights</p>
<p><b>Value/Consideration</b>  Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>Nil – issue of shares on conversion of share rights on 14 April 2024 according to their terms of issue</p>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<u>Direct</u> 5,751,441 Ordinary shares 100,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024 1,000,000 Retention Share Rights  <u>Indirect</u> <i>Banquo Consulting Pty Ltd</i> 5,580,000 Ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights  <i>Angus Caithness SMSF Pty Ltd as trustee for the Caithness Superannuation Fund</i> 150,000 Ordinary shares 150,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Conversion of share rights to fully paid ordinary shares

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

<b>Name of entity</b>	Little Green Pharma Ltd
<b>ACN</b>	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Fleta Jennifer Solomon
<b>Date of last notice</b>	4 October 2023

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Fleta Solomon Super Pty Ltd as trustee for Solomon Super Fund - Ms Solomon is a director of the trustee and beneficiary
<b>Date of change</b>	15 April 2024
<b>No. of securities held prior to change</b>	<p><u>Direct</u> 21,587,216 fully paid ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights 1,000,000 Retention Rights 36,000 Share Rights</p> <p><u>Indirect</u> 250,000 fully paid ordinary shares 250,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024</p>
<b>Class</b>	(a) Fully paid ordinary shares (b) Share rights

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number acquired</b>	(a) 36,000 Fully paid ordinary shares
<b>Number disposed</b>	(b) 36,000 Share Rights
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil – issue of shares on conversion of share rights on 14 April 2024 according to their terms of issue
<b>No. of securities held after change</b>	<p><u>Direct</u>            21,623,216 fully paid ordinary shares            500,000 Class F Performance Rights            500,000 Class G Performance Rights            500,000 Class H Performance Rights            500,000 Class I Performance Rights            500,000 Class J Performance Rights            500,000 Class K Performance Rights            1,000,000 Retention Rights</p> <p><u>Indirect</u>            250,000 fully paid ordinary shares            250,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024</p>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Conversion of share rights to fully paid ordinary shares

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
--	----

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.